NAPROSYN tablett Eesti - eesti - Ravimiamet

naprosyn tablett

roche products limited - naprokseen - tablett - 500mg 56tk

SILDENAFIL ACCORD 50 MG õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

sildenafil accord 50 mg õhukese polümeerikattega tablett

accord healthcare b.v. - sildenafiil - õhukese polümeerikattega tablett - 50mg 12tk; 50mg 4tk; 50mg 24tk; 50mg 2tk

VISUCLOBEN silmatilgad, suspensioon Eesti - eesti - Ravimiamet

visucloben silmatilgad, suspensioon

visufarma spa - klobetasoon - silmatilgad, suspensioon - 1mg 1ml 10ml 1tk

PARAMAX suukaudse lahuse pulber kotikeses Eesti - eesti - Ravimiamet

paramax suukaudse lahuse pulber kotikeses

vitabalans oy - paratsetamool - suukaudse lahuse pulber kotikeses - 500mg 12tk; 500mg 6tk; 500mg 10tk; 500mg 24tk; 500mg 20tk; 500mg 30tk

ESTAN õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

estan õhukese polümeerikattega tablett

medochemie limited - estsitalopraam - õhukese polümeerikattega tablett - 15mg 100tk; 15mg 20tk; 15mg 14tk; 15mg 180tk; 15mg 30tk; 15mg 56tk; 15mg 28tk; 15mg 1000tk; 15mg 90tk

ALPRAZOLAM KRKA tablett Eesti - eesti - Ravimiamet

alprazolam krka tablett

krka d.d. novo mesto - alprasolaam - tablett - 1mg 20tk; 1mg 10tk; 1mg 50tk; 1mg 60tk; 1mg 100tk; 1mg 30tk

Rispoval IBR-Marker Vivum süstesuspensiooni lüofilisaat ja lahusti Eesti - eesti - Ravimiamet

rispoval ibr-marker vivum süstesuspensiooni lüofilisaat ja lahusti

zoetis belgium - veiste rinotrahheiidi viirusvaktsiin - süstesuspensiooni lüofilisaat ja lahusti - 50annus 1tk; 10annus 1tk

RIVAROXABAN STADA õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

rivaroxaban stada õhukese polümeerikattega tablett

stada arzneimittel ag - rivaroksabaan - õhukese polümeerikattega tablett - 10mg 98tk; 10mg 28tk; 10mg 10tk; 10mg 42tk

Comirnaty Euroopa Liit - eesti - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Trifexis Euroopa Liit - eesti - EMA (European Medicines Agency)

trifexis

eli lilly and company limited - spinosaad, milbemütsiin oxime - antibakteriaalsed tooted, insektitsiidid ja repellendid, endectocides - koerad - ravi ja ennetamine flea (ctenocephalides felis) levikust, koerad, kui üks või mitu järgmistest märgetest on vaja samaaegselt: ennetamine heartworm haigus (l3, l4 dirofilaria immitis);ennetamine angiostrongylosis, vähendades tase nakatumise ebaküps täiskasvanud (l5) angiostrongylus vasorum;ravi seedetrakti nematood poolt põhjustatud infektsioonide hookworm (l4, ebaküps täiskasvanud, l5) ning täiskasvanute ancylostoma caninum), ümarussid (ebaküps täiskasvanud l5, ja täiskasvanud toxocara canis ja täiskasvanud toxascaris leonina) ja whipworm (täiskasvanud trichuris vulpis).